Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Remo H.M. Furtado,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
Reads0
Chats0
TLDR
GLP1-RA and SGLT2i reduce atherosclerotic MACE to a similar degree in patients with established atherosclerosis cardiovascular disease, whereas SGLG2i has a more marked effect on preventing hospitalization for heart failure and progression of kidney disease.Abstract:
Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce car...read more
Citations
More filters
Journal ArticleDOI
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +9 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
TL;DR: Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.
Journal ArticleDOI
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Geltrude Mingrone,Peter Rossing,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +12 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen,Søren Lund Kristensen,Rasmus Rørth,Rasmus Rørth,Pardeep S. Jhund,Kieran F. Docherty,Naveed Sattar,David Preiss,Lars Køber,Mark C. Petrie,John J.V. McMurray +10 more
TL;DR: Overall, GLP-1 receptor agonist treatment reduced MACE by 12% and there was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Journal ArticleDOI
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher,Larissa Shamseer,Mike Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Paul G. Shekelle,Lesley A. Stewart +7 more
TL;DR: A reporting guideline is described, the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015), which consists of a 17-item checklist intended to facilitate the preparation and reporting of a robust protocol for the systematic review.
Journal ArticleDOI
Conducting Meta-Analyses in R with the metafor Package
TL;DR: The metafor package provides functions for conducting meta-analyses in R and includes functions for fitting the meta-analytic fixed- and random-effects models and allows for the inclusion of moderators variables (study-level covariates) in these models.
Journal ArticleDOI
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer,David Moher,Mike Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Paul G. Shekelle,Lesley A. Stewart +7 more
TL;DR: The PRISMA-P checklist as mentioned in this paper provides 17 items considered to be essential and minimum components of a systematic review or meta-analysis protocol, as well as a model example from an existing published protocol.